PerkinElmer Receives 2008 Life Science Industry Award for Achievement in High Throughput Screening

PerkinElmer announced that it has received top honors in the Life Science Industry Awards for High Throughput Screening (HTS) and Analysis Systems. For the second consecutive year, the Company was named a winner in the Life Science Industry Awards, which are determined based on the input of nearly 4,500 scientists worldwide, and recognize life science companies offering best-in-class technology and service over the past year.

"We are honored to once again be recognized for our contributions to High Throughput Screening by the worldwide scientific community," said Dr. Richard M. Eglen, president, Bio-discovery, PerkinElmer, Inc. "What makes this award special, apart from the fact that PerkinElmer has won this category two years running, is that scientists in cutting-edge research labs clearly recognize that our solutions continue to provide them with the critical technology and support they need to enable their work. We remain committed to serving these customers and extending our leadership in HTS technologies for advanced cellular research and drug discovery."

"The results of this year's voting confirm the Winners' continued commitment to excellence in the technologies and services they deliver to their scientific customers," said Bill Kelly, president, BioInformatics, LLC. "PerkinElmer has won this category again because scientists clearly value the Company's integrated, powerful platforms for drug discovery. One of their key strengths is in the percentage of their customers who say it's 'highly likely' that they re-purchase HTS solutions from PerkinElmer."

PerkinElmer offers a comprehensive portfolio of enabling HTS technologies including cell-based and biological assays and reagents, detection instruments, microplates and automated liquid handling platforms. These technologies are designed to collectively provide a complete solution by delivering maximum versatility, reliability, performance and the speed for HTS.

The Company continues to expand its product portfolio to address key targets by focusing on powerful new cell-based screening and analysis solutions for G protein-coupled receptors (GPCRs), kinases and preclinical biomarker screening. To meet the demand of drug research laboratories worldwide, PerkinElmer has also enhanced its product portfolio in radioligands and radionucleotides. The Company also continues to be a leader in cellular imaging and analysis, by providing innovative instrumentation and software for confocal cell imaging.

Source: PerkinElmer Instruments